COMPASS Pathways granted fifth US patent for crystalline psilocybin

COMPASS Pathways plc announced today that it has been granted its fifth patent by the US Patent and Trademark Office.

Category Press Release
Country United Kingdom

Companies Featured

COMPASS Pathways
COMPASS Pathways is a publicly listed company (NASDAQ) that is developing psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. COMPASS is one of the largest psychedelic companies and has received substantial investment from atai.